Last10K.com

Bluebird Bio, Inc. (BLUE) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Bluebird Bio, Inc.

CIK: 1293971 Ticker: BLUE

 

Exhibit 99.1

bluebird bio Reports Fourth Quarter and Full Year 2014 Financial Results and Recent Operational Progress

CAMBRIDGE, Mass., February 25, 2015 – bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage

company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2014.

“Over the last year, bluebird bio’s efforts advanced the field of gene therapy, driving us closer to our goal of transforming the lives of patients with severe genetic and rare diseases,” said Nick Leschly, chief bluebird. “In 2014, we presented groundbreaking clinical data in treating beta-thalassemia and were the first in the field to use gene therapy to treat a patient with sickle cell disease. We also acquired gene editing capabilities, strengthened our team and added a substantial amount of cash to our balance sheet, positioning us well to advance to our next stage of development. In 2015, our priorities include completing patient enrollment and obtaining more data from our ongoing clinical programs, defining the regulatory pathways to bring our product candidates to patients and continuing to advance our pipeline of promising immunotherapy and gene therapy programs.”

Recent bluebird Highlights

·

Presented data from beta-thalassemia program at the American Society of Hematology (ASH) annual meeting. In December 2014, bluebird bio presented data from its Northstar and HGB-205 studies demonstrating that the first four beta-thalassemia major patients treated with LentiGlobin® were transfusion free. The Northstar Study is an ongoing, open-label, single-dose, international, multi-center Phase 1/2 study designed to evaluate the safety and efficacy of LentiGlobin for the treatment of subjects with beta-thalassemia major. The HGB-205 study is an ongoing, open-label, single-center Phase 1/2 study designed to evaluate the safety and efficacy of LentiGlobin in the treatment of subjects with beta-thalassemia major and severe sickle cell disease. The data presented at ASH build upon data presented in June 2014 from the HGB-205 study at the European Hematology Association (EHA) annual meeting.

·

Advanced sickle cell disease program. In October 2014, as part of the HGB-205 study, bluebird bio became the first company to treat a sickle cell disease patient with gene therapy. The company also initiated the HGB-206 study, an open-label, multi-center, U.S.-based Phase 1 study designed to evaluate the safety and efficacy of LentiGlobin for the treatment of subjects with severe sickle cell disease.

·

Received Breakthrough Therapy designation for LentiGlobin. In January 2015, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to LentiGlobin for the treatment of transfusion-dependent patients with beta-thalassemia major. The Breakthrough Therapy designation is supported by data from the ongoing Phase 1/2 Northstar and HGB-205 studies of LentiGlobin.

·

Advanced enrollment in CCALD trial.  bluebird bio continued to enroll patients in its Starbeam Study, a Phase 2/3 study designed to evaluate the safety and efficacy of Lenti-D™ in the treatment of subjects with childhood cerebral adrenoleukodystrophy (CCALD).

·

Strengthened balance sheet. In 2014, bluebird bio raised approximately $353 million in net proceeds to fund operations, including an equity financing in December 2014 that raised approximately $243 million and an equity financing in July 2014 that raised approximately $110 million.


The following information was filed by Bluebird Bio, Inc. (BLUE) on Wednesday, February 25, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Bluebird Bio, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bluebird Bio, Inc..

Continue

Assess how Bluebird Bio, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bluebird Bio, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit)
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit) (parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
401(k) Savings Plan
401(k) Savings Plan - Additional Information (detail)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (tables)
Accrued Expenses And Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (detail)
Business Combinations
Business Combinations (tables)
Business Combinations - Additional Information (detail)
Business Combinations - Estimated Fair Value Of Assets Acquired And Liabilities Assumed (detail)
Business Combinations - Schedule Of Acquisition-date Fair Value (detail)
Business Combinations - Schedule Of Estimated Amortization Of Intangible Assets (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Future Minimum Commitments Under Facility Operating Leases (detail)
Common Stock And Preferred Stock
Common Stock And Preferred Stock (tables)
Common Stock And Preferred Stock - Additional Information (detail)
Common Stock And Preferred Stock - Summary Of Future Issuance Of Common Stock Shares (detail)
Description Of The Business
Description Of The Business - Additional Information (detail)
Fair Value Measurements
Fair Value Measurements (tables)
Fair Value Measurements - Additional Information (detail)
Fair Value Measurements - Recorded Amount Of Assets And Liabilities Measured At Fair Value On Recurring Basis (detail)
Fair Value Measurements - Roll-forward Of Fair Value Of The Company's Contingent Consideration Obligations (detail)
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Net Deferred Tax Assets (detail)
Income Taxes - Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate To Effective Income Tax Rate As Reflected In The Financial Statements (detail)
Income Taxes - Schedule Of Components Of Loss Before Income Taxes (detail)
Income Taxes - Summary Of Income Tax Expense (benefit) (detail)
Marketable Securities
Marketable Securities (tables)
Marketable Securities - Additional Information (detail)
Marketable Securities - Summary Of Available For Sale Securities Held (detail)
Net Loss Per Share
Net Loss Per Share (tables)
Net Loss Per Share - Common Stock Equivalents Excluded From Calculation Of Diluted Net Loss Per Share (detail)
Property And Equipment, Net
Property And Equipment, Net (tables)
Property And Equipment, Net - Additional Information (detail)
Property And Equipment, Net - Property And Equipment (detail)
Restricted Cash
Restricted Cash - Additional Information (detail)
Selected Quarterly Financial Data (unaudited)
Selected Quarterly Financial Data (unaudited) (tables)
Selected Quarterly Financial Data - Quarterly Financial Information (detail)
Selected Quarterly Financial Data - Quarterly Financial Information (parenthetical) (detail)
Significant Agreements
Significant Agreements - Additional Information (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (detail)
Stock-based Compensation - Assumptions Used For The Black-scholes Option-pricing Model To Determine The Per Share Weighted Average Fair Value For Options Granted (detail)
Stock-based Compensation - Summary Of Restricted Common Stock Awards (detail)
Stock-based Compensation - Summary Of Restricted Stock Units(detail)
Stock-based Compensation - Summary Of Stock Option Activity Under Plan (detail)
Stock-based Compensation - Summary Of Stock-based Compensation Expense By Award Type (detail)
Subsequent Events
Summary Of Significant Accounting Policies And Basis Of Presentation
Summary Of Significant Accounting Policies And Basis Of Presentation (policies)
Summary Of Significant Accounting Policies And Basis Of Presentation (tables)
Summary Of Significant Accounting Policies And Basis Of Presentation - Additional Information (detail)
Summary Of Significant Accounting Policies And Basis Of Presentation - Estimated Useful Lives Of Assets (detail)
Warrants
Warrants (tables)
Warrants - Additional Information (detail)
Warrants - Fair Value Of Warrant To Purchase Shares (detail)
Warrants - Summary Of Changes In Fair Value Preferred Stock Warrant Liability (detail)
Warrants - Warrants Outstanding (detail)

Material Contracts, Statements, Certifications & more

Bluebird Bio, Inc. provided additional information to their SEC Filing as exhibits

Ticker: BLUE
CIK: 1293971
Form Type: 10-K Annual Report
Accession Number: 0001564590-15-000948
Submitted to the SEC: Wed Feb 25 2015 4:15:55 PM EST
Accepted by the SEC: Wed Feb 25 2015
Period: Wednesday, December 31, 2014
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/blue/0001564590-15-000948.htm